Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA

Journal of Psychopharmacology

Volumn 23, Issue 8, 2009, Pages 923-935

  Hasler, F ^a   Studerus, E ^a   Lindner, K ^a   Ludewig, S ^a   Vollenweider, F X ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

3,4 methylenedioxymethamphetamine; 5 HT1A; Cognition; Ecstasy; Human study; MDMA; Pindolol

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PINDOLOL; PLACEBO; SEROTONIN 1A RECEPTOR;

ADULT; ANXIETY; ARTICLE; ATTENTION; BODY WEIGHT; BRAIN FUNCTION; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; HUMAN; MALE; MENTAL PERFORMANCE; MODULATION; MOOD; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOPHARMACOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPATIAL MEMORY; TASK PERFORMANCE; THERAPY EFFECT; VISUAL MEMORY;

ADULT; AFFECT; ANXIETY; COGNITION; DOUBLE-BLIND METHOD; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PINDOLOL; RECEPTOR, SEROTONIN, 5-HT1A;

EID: 70449419977     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108094650     Document Type: Article

References (72)

1. Bankson, MG, Cunningham, KA (2001) 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297: 846-852.
2. Barnes, NM, Sharp, T. (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083-1152.
3. Baumann, MH, Wang, X., Rothman, RB (2007) 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189: 407-424.
4. Callaway, CW, Rempel, N., Peng, RY, Geyer, MA (1992) Serotonin 5-HT1-like receptors mediate hyperactivity in rats induced by 3,4- methylenedioxymethamphetamine. Neuropsychopharmacology 7: 113-127.
5. Carli, M., Luschi, R., Samanin, R. (1995) (S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Eur J Pharmacol 283: 133-139.
6. Colado, MI, OShea, E., Green, AR (2004) Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 173: 249-263.
7. Coull, JT, Frith, CC, Frackowiak, RSJ, Grasby, PM (1996) A frontoparietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia 34: 1085-1095.
8. Derogatis, LR, Lipman, RS, Covi, L. (1976) SCL-90 (Symptom-Check-List). Self-report symptom inventory. In: Guy, W, (ed). ECDEU assessement manual for psychopharmacology. Rockville / Maryland: NIMH.
9. Dittrich, A. (1994) Psychological aspects of altered states of consciousness of the LSD type: measurements of their basic dimensions and prediction of individual differences. In: Pletscher, A, Ladewig, D, (eds) 50 Years of LSD. Current status and perspectives of hallucinogens. New York: Parthenon Publishing, pp. 101-118.
10. Dittrich, A. (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31: 80-84.
11. Dittrich, A., von Arx, S., Staub, S. (1985) International study on altered states of consciousness (ISASC). Summary of the results. German J Psychol 9: 319-339.
12. Downing, J. (1986) The psychological and physiological effets of MDMA on normal volunteers. J Psychoactive Drugs 18: 335-340. Fahrenberg, J., Hampel, R., Selg, H. (1984) Das Freiburger Pers¶nlichkeitsinventar FPI, fourth ed. D-G¶ttingen: Hogrefe.
13. Fitzgerald, JL, Reid, JJ (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 191: 217-220.
14. Gartside, SE, McQuade, R., Sharp, T. (1997) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on 5-HT cell firing and release: comparison between dorsal and median raphe 5-HT systems. Neuropharmacology 36: 1697-1703.
15. Gouzoulis-Mayfrank, E. (1999) Wirkungen und Risiken des Ecstasy-Konsums. In: Thomasius, R (ed.). Ecstasy - Wirkungen, Risiken, Interventionen. D-Stuttgart: Ferdinand Enke Verlag.
16. Green, AR, Cross, AJ, Goodwin, GM (1996) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl) 119: 247-260.
17. Green, AR, Mechan, AO, Elliott, JM, OShea, E., Colado, MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55: 463-508.
18. Greer, G., Tolbert, R. (1986) Subjective reports on the effects of MDMA in a clinical setting. J Psychoactive Drugs 18: 319-327. Gudelsky, GA, Nash, JF (1996) Carrier-mediated release of serotonin by 3,4- methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66: 243-249.
19. Hekmatpanah, CR, Peroutka, SJ (1990) 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4- methylenedioxymethamphetamine and related agents. Eur J Pharmacol 177: 95-98.
20. Hermle, L., Spitzer, M., Borchardt, D., Kovar, KA, Gouzoulis, E. (1993) Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents. Neuropsychopharmacology 8: 171-176.
21. Iravani, MM, Asari, D., Patel, J., Wieczorek, WJ, Kruk, ZL (2000) Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices. Synapse 36: 275-285.
22. Jacobs, BL, Azmitia, EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72: 165-229.
23. Jakala, J., Sirvio, M., Riekkinen, E., Koivisto, K., Kejonen, M., Vanhanen, M., et al. (1999) Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans. Neuropsychopharmacology 20: 119-130.
24. Janke, W., Debus, G. (1978) Die Eigenschaftsw¶rterliste (EWL-K) - Ein Verfahren zur Erfassung der Befindlichkeit, first ed. D-G¶ttingen: Hogrefe.
25. KankaanpCurrency signCurrency sign, A., Meririnne, E., Lillsunde, P., SeppCurrency signlCurrency sign, T. (1998) The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 59: 1003-1009.
26. Koch, S., Galloway, MP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104: 135-146. Lieberman, JA, Aghajanian, GK (1999) Caveat emptor: researcher beware. Neuropsychopharmacology 21: 471-473.
27. Liechti, ME, Baumann, C., Gamma, A., Vollenweider, FX (2000 a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22: 513-521.
28. Liechti, ME, Gamma, A., Vollenweider, FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154: 161-168.
29. Liechti, ME, Saur, MR, Gamma, A., Hell, D., Vollenweider, FX (2000 b) Psychological and physiological effects o MDMA ("Ecstasy") after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23: 396-405.
30. McCreary, AC, Bankson, MG, Cunningham, KA (1999) Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/ 1D) receptors. J Pharmacol Exp Ther 290: 965-973.
31. Mehta, MA, Swainson, R., Ogilvie, AD, Sahakian, J., Robbins, TW (2001) Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers. Psychopharmacology 159: 10-20.
32. Meneses, A. (1999) 5-HT system and cognition. Neurosci Biobehav Rev 23: 1111-1125.
33. Millan, MJ, Colpaert, FC (1991) Methylenedioxymethamphetamine induces spontaneous tail-flicks in the rat via 5-HTa1 receptors. Eur J Pharmacol 193: 145-152.
34. Morley, KC, Arnold, JC, McGregor, IS (2005) Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 29: 648-657.
35. Morton, J. (2005) Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 5: 79-86.
36. Muller, CP, Carey, RJ, Huston, JP, De Souza Silva, MA (2007) Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors. Prog Neurobiol 81: 133-178.
37. Nash, JF, Meltzer, HY, Gudelsky, GA (1988) Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245: 873-879.
38. Nichols, DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classical hallucinogens. Identification of a new therapeutic class: Entactogens. J Psychoactive Drugs 18: 305-313.
39. Nichols, DE (2004) Hallucinogens. Pharmacol Ther 101: 131-181. Nichols, DE, Lloyd, DH, Hoffman, AJ, Nichols, MB, Yim, GK (1982) Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. J Med Chem 25: 530-535.
40. Park, S., Holzman, PS (1993) Association of working memory deficit and eye tracking dysfunction in schizophrenia. Schizophr Res 11: 55-61.
41. Peroutka, SJ, Newman, H., Harris, H. (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1: 273-277.
42. Rabiner, EA, Gunn, RN, Castro, ME, Sargent, PA, Cowen, PJ, Koepp, MJ, et al. (2000) Beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro. Implications for antidepressant therapy. Neuropsychopharmacology 23: 285-293.
43. Rabiner, EA, Gunn, RN, Wilkins, MR, Sargent, PA, Mocaer, E., Sedman, E., et al. (2000) Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY- 100635. Nucl Med Biol 27: 509-513.
44. Ramoska, E., Sacchetti, AD (1985) Propranolol-induced hypertension in treatment of cocaine intoxication. Ann Emerg Med 14: 1112-1113.
45. Riedel, WJ, Eikmans, K., Heldens, A., Schmitt, JA (2005) Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J Psychopharmacol 19: 12-20.
46. Robbins, TW, James, M., Owen, AM, Sahakian, BJ, Lawrence, AD, McInnes, L., et al. (1998) A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. J Int Neuropsychol Soc 4: 474-490.
47. Robbins, TW, James, M., Owen, AM, Sahakian, BJ, Mcinnes, L., Rabbitt, P. (1994) Cambridge Neuropsychological Test Automated Battery (CANTAB). a factor analytic study of a large sample of normal elderly volunteers. Dementia 5: 266-281.
48. Robbins, TW, Semple, J., Kumar, R., Truman, MI, Shorter, J., Ferraro, A., et al. (1997) Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: comparison with diazepam and implications fort dementia. Psychopharmacology 134: 95-106.
49. Roth, BL, Willins, DL, Kristiansen, K., Kroeze, WK (1999) Activation is hallucinogenic and antagonism is therapeutic: role of 5- HT(2A) receptors in atypical antipsychotic drug actions. Neuroscientist 5: 262.
50. Rothman, RB, Baumann, MH (2002) Serotonin releasing agents neurochemical, therapeutic and adverse effects. Pharmacol Biochem Behav 71: 825-836.
51. Rudnick, G., Wall, SC (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxy- methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89: 1817-1821.
52. Sadzot, B., Baraban, JM, Glennon, RA, Lyon, RA, Leonhardt, S., Jan, CR, et al. (1989) Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology 98: 495-499.
53. Sanghavi, NM, Venkatesh, H., Mahalaxmi, D., Shiravadekar, HS (1995) In vivo evaluation of pindolol multi-unit dosage forms. Drug Dev Ind Pharmacy 21: 1917-1921.
54. Santucci, AC, Knott, PJ, Haroutunian, V. (1996) Excessive serotonin release, not depletion, leads to memory impairments in rats. Eur J Pharmacol 295: 7-17.
55. Schmidt, CJ, Black, CK, Abbate, GM, Taylor, VL (1990) Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res 529: 85-90.
56. Schmidt, CJ, Taylor, VL (1987) Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36: 4095-4102.
57. Schmitt, JA, Ramaekers, JG, Kruizinga, MJ, van Boxtel, MP, Vuurman, EF, Riedel, WJ (2002) Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 16: 207-214.
58. Schuster, P., Wittchen, HU (1996) Ecstasy-und Halluzinogengebrauch bei Jugendlichen - gibt es eine Zunahme. Verhaltenstherapie 6: 222-232.
59. Spielberger, CD, Gorsuch, RL, Lusheme, RE (1970) STAI, Manual for the State-Trait-Anxiety-Inventory. USA- Palo Alto: Consulting Psychologists Press.
60. Sprouse, JS, Bradberry, CW, Roth, RH, Aghajanian, GK (1989) MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin. Eur J Pharmacol 167: 375-383.
61. StatSoft (1995) STATISTICA for Windows, 5.1 ed. Tulsa, USA: StatSoft, Inc.
62. Tei, H., Soma, Y., Maruyama, S. (1993) Neuropsychological investigation in multiple sclerosis (article in Japanese). No To Shinkei 45: 133-137.
63. Thompson, MR, Callaghan, PD, Hunt, GE, Cornish, JL, McGregor, IS (2007) A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4-methylenedioxymethamphetamine ("ecstasy"). Neuro-science 146: 509-514.
64. Vollenweider, FX, Gamma, A., Liechti, ME, Huber, T. (1998 a) Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") on MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241-251.
65. Vollenweider, FX, Gamma, A., Liechti, ME, Huber, T. (1999 a) Is a single dose MDMA harmless. Neuropsychopharmacology 21: 598-600.
66. Vollenweider, FX, Remensberger, S., Hell, D., Geyer, MA (1999 b) Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmascology (Berl) 143: 365-372.
67. Vollenweider, FX, Vollenweider-Scherpenhuyzen, MFI, BCurrency signbler, A., Vogel, H., Hell, D. (1998 b) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-3902.
68. Whitaker-Azmitia, PM, Aronson, TA (1989) " Ecstasy" (MDMA)-induced panic. Am J Psychiatry 146: 119.
69. Williamson, S., Gossop, M., Powis, B., Griffiths, P., Fountain, J., Strang, J. (1997) Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 44: 87-94.
70. Wingen, M., Kuypers, KP, Ramaekers, JG (2007) The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers. Psychopharmacology (Berl) 190: 391-400.
71. Wittchen, HU, Pfister, H. (1997) DIA-X-Interview. D- Frankfurt: Swets Test Services.
72. Yamamoto, BK, Spanos, LJ (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awakebehavig rat. Eur J Pharmacol 148: 195-203.